
Amplia Leads Early Gains on ASX 200 as Broader Market Stalls
Highlights Amplia Therapeutics surges on clinical update in pancreatic cancer trial ASX 200 dampened by declines in tech, energy, and materials sectors Bank stocks and selective healthcare names provide morning stability The Australian share market opened …